0DPB Stock Chart & Stats
kr216.17
-kr2.30(-1.30%)
At close: 4:00 PM EDT
kr216.17
-kr2.30(-1.30%)
Day’s Range― - ―
52-Week Rangekr171.60 - kr242.30
Previous CloseN/A
Volume18.09K
Average Volume (3M)66.30K
Market Cap
kr17.27B
Enterprise Valuekr11.65K
Total Cash (Recent Filing)kr1.24B
Total Debt (Recent Filing)kr116.96M
Price to Earnings (P/E)10.8
Beta1.09
Next Earnings
Nov 13, 2026EPS Estimate
5.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.74
Shares Outstanding79,236,725
10 Day Avg. Volume55,431
30 Day Avg. Volume66,299
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bavarian Nordic AS News
0DPB FAQ
What was Bavarian Nordic AS’s price range in the past 12 months?
Bavarian Nordic AS lowest share price was kr171.60 and its highest was kr242.30 in the past 12 months.
What is Bavarian Nordic AS’s market cap?
Bavarian Nordic AS’s market cap is kr17.27B.
When is Bavarian Nordic AS’s upcoming earnings report date?
Bavarian Nordic AS’s upcoming earnings report date is Nov 13, 2026 which is in 77 days.
How were Bavarian Nordic AS’s earnings last quarter?
Bavarian Nordic AS released its earnings results on Aug 21, 2026. The company reported kr9.4 earnings per share for the quarter, beating the consensus estimate of kr3.15 by kr6.25.
Is Bavarian Nordic AS overvalued?
According to Wall Street analysts Bavarian Nordic AS’s price is currently Overvalued.
Does Bavarian Nordic AS pay dividends?
Bavarian Nordic AS does not currently pay dividends.
What is Bavarian Nordic AS’s EPS estimate?
Bavarian Nordic AS’s EPS estimate is 5.3.
How many shares outstanding does Bavarian Nordic AS have?
Bavarian Nordic AS has 79,236,725 shares outstanding.
What happened to Bavarian Nordic AS’s price movement after its last earnings report?
Bavarian Nordic AS reported an EPS of kr9.4 in its last earnings report, beating expectations of kr3.15. Following the earnings report the stock price went up 9.063%.
Which hedge fund is a major shareholder of Bavarian Nordic AS?
Currently, no hedge funds are holding shares in GB:0DPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bavarian Nordic AS
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.